Glaucoma Trial, Recruiting NCT04416724 Sponsor: Nova Scotia Health Authority Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT04416724
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have pseudoexfoliation syndrome — a condition where a flaky, dandruff-like material builds up in the eye — confirmed by an eye doctor using a specialised lamp examination
  • People whose eye doctor has decided that their eye pressure needs to be lowered, either because of pseudoexfoliation-related glaucoma or because the eye pressure is high enough to need treatment, even if no nerve damage or vision loss has been found yet
  • People who have an early cataract (clouding of the eye's lens) that is not yet causing noticeable symptoms

Who may not be able to join:

  • People under 50 years of age
  • People whose eye doctor finds that the drainage angle inside the eye is significantly closed (a finding from a specific eye examination called gonioscopy)
  • People who have previously had a procedure to lower eye pressure, such as laser treatment (trabeculoplasty), trabeculectomy, or minimally invasive glaucoma surgery
  • People who have used eye pressure-lowering medication for more than 6 months in total
  • People who have certain eye or whole-body conditions, or who take medications, that could significantly affect eye pressure — such as eye inflammation (uveitis), certain types of glaucoma caused by new blood vessels or injury, corneal conditions that affect pressure measurement, or regular use of steroid tablets
  • People whose eye pressure at the start of the study is higher than 36 mmHg (a unit used to measure eye pressure)
  • People who already have significant vision field damage at the start of the study (confirm with trial site)
  • People who are unable or unwilling to give voluntary, informed consent to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 902-473-2839

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Nova Scotia Health Authority
Registry
ClinicalTrials.gov
Start date
10 October 2022
Est. completion
1 August 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Medication-free intraocular pressure control

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov